Devyser Diagnostics AB (DVYSR) - Net Assets
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has net assets worth Skr357.90 Million SEK (≈ $38.52 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr470.10 Million ≈ $50.59 Million USD) and total liabilities (Skr112.20 Million ≈ $12.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Devyser Diagnostics AB tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr357.90 Million |
| % of Total Assets | 76.13% |
| Annual Growth Rate | 42.31% |
| 5-Year Change | -14.97% |
| 10-Year Change | N/A |
| Growth Volatility | 439.49 |
Devyser Diagnostics AB - Net Assets Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's net assets have evolved over time, based on quarterly financial data. See Devyser Diagnostics AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Devyser Diagnostics AB (2018–2025)
The table below shows the annual net assets of Devyser Diagnostics AB from 2018 to 2025. For live valuation and market cap data, see Devyser Diagnostics AB (DVYSR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr354.30 Million ≈ $38.13 Million |
+1.52% |
| 2024-12-31 | Skr349.00 Million ≈ $37.56 Million |
-9.37% |
| 2023-12-31 | Skr385.10 Million ≈ $41.44 Million |
-10.74% |
| 2022-12-31 | Skr431.44 Million ≈ $46.43 Million |
+3.54% |
| 2021-12-31 | Skr416.68 Million ≈ $44.84 Million |
+1254.05% |
| 2020-12-31 | Skr30.77 Million ≈ $3.31 Million |
-16.85% |
| 2019-12-31 | Skr37.01 Million ≈ $3.98 Million |
+23.50% |
| 2018-12-31 | Skr29.97 Million ≈ $3.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Devyser Diagnostics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18645700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.00 Million | 0.28% |
| Other Comprehensive Income | Skr2.60 Million | 0.73% |
| Other Components | Skr545.60 Million | 153.99% |
| Total Equity | Skr354.30 Million | 100.00% |
Devyser Diagnostics AB Competitors by Market Cap
The table below lists competitors of Devyser Diagnostics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
$162.26 Million |
|
Zhejiang Zone King Environmental Sci&Tech Co Ltd
SHG:688701
|
$162.30 Million |
|
Li Peng Enterprise Co Ltd
TW:1447
|
$162.38 Million |
|
Samjin Pharm
KO:005500
|
$162.40 Million |
|
Shane Global Holding Inc
TW:8482
|
$162.22 Million |
|
BioInvent International AB
ST:BINV
|
$162.17 Million |
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
$162.15 Million |
|
Shriram Properties Limited
NSE:SHRIRAMPPS
|
$162.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Devyser Diagnostics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 349,100,000 to 354,300,000, a change of 5,200,000 (1.5%).
- Net loss of 8,400,000 reduced equity.
- New share issuances of 9,400,000 increased equity.
- Other comprehensive income increased equity by 2,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.40 Million | -2.37% |
| Share Issuances | Skr9.40 Million | +2.65% |
| Other Comprehensive Income | Skr2.00 Million | +0.56% |
| Other Changes | Skr2.20 Million | +0.62% |
| Total Change | Skr- | 1.49% |
Book Value vs Market Value Analysis
This analysis compares Devyser Diagnostics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.00x to 4.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr9.98 | Skr89.80 | x |
| 2019-12-31 | Skr12.20 | Skr89.80 | x |
| 2020-12-31 | Skr10.60 | Skr89.80 | x |
| 2021-12-31 | Skr37.10 | Skr89.80 | x |
| 2022-12-31 | Skr27.10 | Skr89.80 | x |
| 2023-12-31 | Skr23.80 | Skr89.80 | x |
| 2024-12-31 | Skr21.29 | Skr89.80 | x |
| 2025-12-31 | Skr21.35 | Skr89.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Devyser Diagnostics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.35%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.33x
- Recent ROE (-2.37%) is above the historical average (-8.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 1.73% | 1.08% | 1.00x | 1.61x | Skr-2.48 Million |
| 2019 | 18.94% | 10.90% | 0.87x | 1.99x | Skr3.31 Million |
| 2020 | -35.46% | -16.61% | 0.88x | 2.42x | Skr-13.99 Million |
| 2021 | -4.97% | -22.17% | 0.20x | 1.10x | Skr-62.40 Million |
| 2022 | -10.65% | -36.29% | 0.25x | 1.16x | Skr-89.10 Million |
| 2023 | -13.92% | -31.66% | 0.33x | 1.32x | Skr-92.11 Million |
| 2024 | -17.62% | -28.35% | 0.46x | 1.36x | Skr-96.41 Million |
| 2025 | -2.37% | -3.35% | 0.53x | 1.33x | Skr-43.83 Million |
Industry Comparison
This section compares Devyser Diagnostics AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $77,776,228
- Average return on equity (ROE) among peers: -46.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Devyser Diagnostics AB (DVYSR) | Skr357.90 Million | 1.73% | 0.31x | $162.24 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $31.21 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $14.78 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $292.61 Million | -8.46% | 0.84x | $53.45 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $120.42 Million |
| Boule Diagnostics AB (BOUL) | $269.60 Million | -82.83% | 1.19x | $13.83 Million |
| CellaVision AB (CEVI) | $48.66 Million | 0.00% | 0.51x | $368.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $33.00 Million | -64.44% | 0.36x | $11.79 Million |
| Chordate Medical Holding AB (CMH) | $35.72 Million | -45.19% | 0.33x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $70.60 Million | -44.20% | 0.45x | $127.56 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more